AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33783067
Drug: BCNU (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU (150 mg/m²) and temozolomide
Trial: 36039789
Drug: 7-day low-salt
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day low-salt diet (3.0 g/day)
Trial: 36039789
Drug: 7-day high-salt
RxNorm normalized name: Salt solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day high-salt diet (18 g/day)
Trial: 33783498
Drug: Rituximab (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (200, 500, 700, and 1000 mg single intravenous dose)
Trial: 33785483
Drug: SINE compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SINE compounds in combination with R-CHOP
Trial: 33785483
Drug: SINE compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SINE compounds
Trial: 33785784
Drug: SARS-CoV-2 RNAemia
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 RNAemia (RNAemia) defined as RNA copies above 1000/ml measured by PCR in plasma
Trial: 33786329
Drug: Low-Molecular Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Molecular Weight Hyaluronic Acid (LMW-HA); n = 14; 3 weekly intra-articular injections.
Trial: 33786329
Drug: Leukocyte-Poor Platelet-Rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP); n = 19; 3 weekly intra-articular injections.
Trial: 33786583
Drug: Duvelisib (Duv)
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Duvelisib (Duv) and Venetoclax (Ven) combination
Trial: 33787078
Drug: ADI-PEG20 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADI-PEG20 plus low-dose cytarabine (LDC)
Trial: 33787078
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LDC)
Trial: 33787401
Drug: Super-selective intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Super-selective intra-arterial indocyanine green (ICG) administration (5 mL bolus at .125 mg/mL)
Trial: 33787401
Drug: Super-selective intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Super-selective intra-arterial indocyanine green (ICG) administration
Trial: 33788415
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase
Trial: 33788415
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) atezolizumab
Trial: 33788611
Drug: Integrative Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Medicine Interventions
Trial: 33788611
Drug: Pain Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Medication
Trial: 33789635
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results, and microbiota analysis.
Trial: 33789635
Drug: Creation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data.
Trial: 33789723
Drug: Left Ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left Ventricular Assist Device (LVAD) as destination therapy
Trial: 33790783
Drug: TangWang Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TangWang Prescription
Trial: 33791217
Drug: HID-PBSCT using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HID-PBSCT using G-PB grafts
Trial: 33791217
Drug: HID HSCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HID HSCT using the combination of G-BM and G-PB grafts
Trial: 33791349
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no routine oxygen therapy)
Trial: 33792221
Drug: CAR-T therapies
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T therapies targeting B-cell maturation antigen (BCMA)
Trial: 33792221
Drug: CAR-T therapies
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T therapies targeting other antigens (SLAMF7 and CD44v6)
Trial: 33792221
Drug: Current autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current autologous CAR-T therapies
Trial: 33792960
Drug: TS-HDS/FGFR3 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-HDS/FGFR3 antibodies
Trial: 39637900
Drug: Alpelisib 300
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1
Trial: 33794207
Drug: Chemoradiotherapy (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2) and MRI-based adaptive brachytherapy (IGABT)
Trial: 33794832
Drug: SensiumVitals™ patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SensiumVitals™ patch measuring temperature, heart & respiratory rates applied on arrival for the duration of stay.
Trial: 33795193
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hENT1-independent adjuvant chemotherapy)
Trial: 33795869
Drug: Intravitreal sepofarsen
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal sepofarsen injection
Trial: 33799685
Drug: Posttransplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant cyclophosphamide (PTCy) 50 mg/kg on days +3 and +4 combined with tacrolimus/mycophenolate mofetil (T/MMF) starting day +5
Trial: 33799685
Drug: Posttransplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant cyclophosphamide (PTCy) 50 mg/kg combined with T/MMF
Trial: 33800872
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (SRT) at 70 Gy in 35 fractions + locoregional deep hyperthermia (HT) (7-10 sessions)
Trial: 33801399
Drug: Trabectedin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin, administered every three weeks, median of four cycles (range: 1-40), mostly as a second-line treatment (~60% of patients)
Trial: 33803049
Drug: solid ASD
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solid ASD of efavirenz 50 mg
Trial: 33803049
Drug: dissolved ASD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dissolved ASD of efavirenz 50 mg
Trial: 33803049
Drug: molecular solution
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: molecular solution of efavirenz 3 mg (non-ASD)
Trial: 33804976
Drug: Calcium-containing Eggshell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-containing Eggshell Powder (ESP) supplementation, 2.4 g daily for 6 months
Trial: 33805731
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT) including radiotherapy with concurrent 5-Fluorouracil (5-FU)/Capecitabine and Oxaliplatin.
Trial: 33807097
Drug: Bivalent oral
RxNorm normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent oral vaccine against enteric fever, specific dosage and duration not mentioned.
Trial: 33807097
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not specified, details on control treatment not available.
Trial: 33809705
Drug: HIV+ and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV+ and low iron stores (inflammation-unadjusted serum ferritin ≤ 40 µg/L)
Trial: 33811727
Drug: Gemcitabine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 800 mg/m²
Trial: 33812913
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose escalation with simultaneous integrated boost (SIB) technique, delivering 62.5-64 Gy/25-32 fractions to GTV, with SIB up to 70 Gy for pre-treatment 50% SUVmax area of GTV, plus 2 cycles of chemotherapy (cisplatin and fluorouracil) concurrently and 2 more cycles after radiotherapy.
Trial: 33812913
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose escalation with SIB (Level 3&4)
Trial: 33812913
Drug: Maximal dose
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal dose of the esophagus (Dmax)
Trial: 33813550
Drug: Dexmedetomidine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine IV administered without a loading dose at age-specific dose regimens 0.2-1.4 µg/kg/hr (< 6 yr) and 0.2-1.0 µg/kg/hr (≥ 6 yr)
Trial: 33813550
Drug: Dexmedetomidine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine IV administered
Trial: 33813580
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of subcutaneous injection risk
Trial: 33813727
Drug: Prasugrel 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 3.75 mg DAPT
Trial: 33813771
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with EDS due to severe sleep-disordered breathing, improving after therapy
Trial: 33813842
Drug: Tailored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored treatment of nonphysiologic hemodynamic adjustments to pregnancy
Trial: 33816283
Drug: Cs-131 implant
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cs-131 implant after surgical resection
Trial: 33816524
Drug: PT-Cy combined
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PT-Cy combined with tacrolimus and low-dose ATG
Trial: 33817379
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac 25 mg/mL applied after laser microporation of cNF, reapplied twice daily for 3 days.
Trial: 33817379
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline applied after laser microporation of cNF, reapplied twice daily for 3 days.
Trial: 33818022
Drug: Adjuvant letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant letrozole (2.5 mg/daily) for 5 years
Trial: 33818226
Drug: Oral anticoagulants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants, alone or in combination with antiplatelet (AP)
Trial: 33820779
Drug: Sapanisertib plus
RxNorm normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib plus exemestane (3 to 5 mg daily in phase IB, 25 mg daily)
Trial: 33820779
Drug: Sapanisertib plus
RxNorm normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib plus fulvestrant (4 mg daily, 500 mg monthly)
Trial: 33820780
Drug: ABBV-085 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-085 monotherapy at 3.6 mg/kg
Trial: 33820780
Drug: ABBV-085 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-085 at 3.6 mg/kg every 14 days
Trial: 33820783
Drug: Pepinemab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pepinemab (10 mg/kg) with Avelumab (10 mg/kg), every 2 weeks
Trial: 33820851
Drug: Secondary antibiotic
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary antibiotic prophylaxis
Trial: 33822526
Drug: CAR-T cell
RxNorm normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cell therapy
Trial: 33823051
Drug: Migraine-specific medications
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine-specific medications
Trial: 33823051
Drug: Acute medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute medication use
Trial: 33823051
Drug: Migraine-specific medication
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine-specific medication use
Trial: 33823783
Drug: Sexual risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual risk reduction intervention in addition to hepatitis C treatment
Trial: 33824433
Drug: Intrabone (IB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrabone (IB) infusion of umbilical cord blood transplantation (UCBT)
Trial: 33824442
Drug: 10-day decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day decitabine (20 mg/m2) combined with fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation (allo HCT)
Trial: 33824476
Drug: Tepotinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepotinib (500 mg daily)
Trial: 33825965
Drug: P2X3-Receptor Antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: P2X3-Receptor Antagonist Gefapixant
Trial: 33825965
Drug: Prior medications
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior medications (inhaled/oral steroids, antihistamines, antacids)
Trial: 33826106
Drug: Ravulizumab (weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (weight-based doses administered on days 1, 5, 10, and 15)
Trial: 33826106
Drug: Ravulizumab (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (modified dosing regimen)
Trial: 33826112
Drug: Eculizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab treatment (a complement C5 inhibitor)
Trial: 33826209
Drug: Omecamtiv mecarbil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil, dosage and duration not available
Trial: 33826362
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (replacing vincristine in the OEPA/COPDac regimen); two cycles of AEPA and four cycles of CAPDac; residual node radiotherapy (25.5 Gy) for non-CR sites after chemotherapy
Trial: 33826695
Drug: Yogurt consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt consumption (per 25 g/d)
Trial: 33826695
Drug: High-fat milk
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat milk consumption (per 100 g/d)
Trial: 33826695
Drug: Total nonfermented
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total nonfermented milk consumption (per 100 g/d)
Trial: 33827114
Drug: Carfilzomib (20/36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg) for 8 cycles followed by transplant and 1 year of lenalidomide maintenance (10 mg)
Trial: 33827114
Drug: Carfilzomib (20/36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg)
Trial: 33827675
Drug: Glucose metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose metabolism in the right middle temporal gyrus (RMTG)
Trial: 33827675
Drug: RMTG metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMTG metabolism
Trial: 33828254
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg once daily plus Pembrolizumab 200 mg every 3 weeks
Trial: 33829030
Drug: Enhanced High-Volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced High-Volume Preparation for Colonoscopy
Trial: 33829030
Drug: Conventional Low-Volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Low-Volume Preparation for Colonoscopy
Trial: 33829237
Drug: Fruit juice
RxNorm normalized name: Fruit Juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit juice intake at 1 year old (120 mL per day)
Trial: 33829355
Drug: CKD-516 in
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-516 in combination with intravenous irinotecan (120 mg/m2), administered for five consecutive days followed by two days off.
Trial: 33829783
Drug: AG-270, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-270, a first-in-class oral MAT2A inhibitor
Trial: 33830058
Drug: treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual
Trial: 33830168
Drug: CE-sparing technique
RxNorm normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction concurrent with standard chemotherapy with or without adjuvant durvalumab.
Trial: 33830168
Drug: Standard chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemoradiation therapy (not explicitly detailed in the abstract).
Trial: 33830168
Drug: CE-sparing technique
RxNorm normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy.
Trial: 33830407
Drug: ASP4132 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4132 5 mg
Trial: 33830407
Drug: ASP4132 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4132 10 mg
Trial: 33830407
Drug: ASP4132 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4132 7.5 mg
Trial: 33830407
Drug: ASP4132 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4132 10 mg intermittent dosing (3 days on, 4 days off)
Trial: 33830407
Drug: ASP4132 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4132 15 mg intermittent dosing (1 day on, 6 days off)
Trial: 33830407
Drug: ASP4132 pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4132 pharmacokinetics
Trial: 33831045
Drug: Low-dose beetroot
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose beetroot juice (BJ) supplementation (nitrate: 1.3 mmol/L)
Trial: 33831045
Drug: High-dose beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beetroot juice (BJ) supplementation (nitrate: 4.3 mmol/L)
Trial: 33831045
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (BJ) supplementation (nitrate: 0.9 mmol/L)
Trial: 33831732
Drug: Cemiplimab 200
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 200 mg every 2 weeks intravenously for up to 48 weeks
Trial: 33831901
Drug: Automated administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated administration of ephedrine or phenylephrine via the ADIVA algorithm
Trial: 33832543
Drug: Virtual family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual family-based treatment (vFBT)
Trial: 33832946
Drug: Subcutaneous N-803
RxNorm normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous N-803 plus rituximab
Trial: 33835229
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg once daily plus letrozole 2.5 mg once daily
Trial: 33835265
Drug: SARS-CoV‑2 IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV‑2 IgG and IgM antibody tests using a high sensitivity/low specificity threshold
Trial: 33835628
Drug: Floatation-Reduced Environmental
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Floatation-Reduced Environmental Stimulation Therapy (REST) for 90 minutes
Trial: 33835866
Drug: Atezolizumab 1,200
RxNorm normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1,200 mg every 3 weeks until disease progression, unacceptable toxicity, loss of clinical benefit, or patient/physician decision